Enzymatica AB (publ) (STO:ENZY)
Sweden · Delayed Price · Currency is SEK 2.760
+0.380 (15.97%)
May 26, 2026, 5:29 PM CET
Enzymatica AB Earnings Call Transcripts
Fiscal Year 2025
-
Recent independent studies show ColdZyme significantly reduces the duration and severity of upper respiratory infections by lowering viral load, with consistent results in both human and cell models. The product was well-tolerated, and findings are expected to apply to the general population.